Clinical features of vaccine-induced immune thrombocytopenia and thrombosis.
12 Aug, 2021 | 09:05h | UTCCommentary: Largest Study of VITT After COVID-19 Vaccination Digs Into Lab, Clinical Features – TCTMD
Related:
NICE COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis.
Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.
Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (several articles and resources on the subject)
Commentary on Twitter
The phenotypes of VITT were defined in 220 patients presenting a 14-day median after the first ChAdOx1 nCoV-19 dose. Mortality was 22%. https://t.co/ir0yG5X0BP #COVID19 #IDTwitter pic.twitter.com/iAfxs0I1Ce
— NEJM (@NEJM) August 11, 2021